Skip to Content
Søk Menu

EADV 2021 | European Academy of Dermatology and Venereology

EADV 2021

The risk of infections in psoriasis patients treated with biologics during the COVID-19 pandemic

  • / Lara van der Schoot / Juul van den Reek

Psoriasis has significant negative impact on quality of life

  • / Dimitrios Ioannides
Andrew Blauvelt

Switching from biology treatment of AD to a JAK inhibitor resulted in improved efficacy

/ Andrew Blauvelt
Atopisk dermatitisEADV21 Play the Video

Almost half of Europeans have a dermatological condition

/ BestPractice Nordic
EADV21

New research on impact of COVID-19 on psoriasis patients

/ BestPractice Nordic
Psoriasiscovid-19EADV21

Nyeste status – Biologisk behandling til børn og unge med atopisk dermatitis

/ BestPractice Nordic
Atopisk dermatitisEADV21
Load more

Del best practice med dine kollegaer

Skriv en artikkel til BestPractice Nordic. Send et forslag til redaksjonen

Send mail til redaksjonen

MEDtalks med ledende spesialister

EADV20: Complete treatment of psoriatic disease

/ Kristian Reich
PsoriasisEADV20 Play the Video

EADV20: Baricitinib – the first JAK-inhibitor for treatment of patients with atopic dermatitis

/ Kristian Reich
Atopisk dermatitisJAK-hemmereEADV20 Play the Video

EADV20: Sonelokinab – an IL-17 A/F Nanobody®, which neutralizes both IL-17A and IL-17F in patients with moderate to severe chronic plaque-type psoriasis

/ Kim Papp
EADV20plakkpsoriasis Play the Video

EADV20: Optimizing outcomes in moderate-to-severe atopic dermatitis

/ Lawrence Eichenfield
Atopisk dermatitisEADV20 Play the Video

EADV20: Biologics increase the risk of being infected with COVID-19, but not the risk of severe disease and death

/ Giovanni Damiani
EADV20covid-19 Play the Video

EADV20: Patienter med psoriasisgigt opnår en højere livskvalitet, når behandlingen bedrer både deres hud og ledgener

/ Lars Erik Kristensen
EADV20 Play the Video
Back to top